Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 6/2019

01-11-2019 | Cardiomyopathy

Cardiogenic shock in cancer

Authors: Kalliopi Keramida, John T. Parissis, Ovidiu Chioncel, Dimitrios Farmakis

Published in: Heart Failure Reviews | Issue 6/2019

Login to get access

Abstract

Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management.
Literature
1.
Tubaro M, Vranckx P, Price S, Vrints C, European Society of C. The ESC textbook of intensive and acute cardiovascular care. 2016
2.
Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, on behalf of the ESC Heart Failure Long-Term Registry Investigators (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(10):1242–1254PubMedCrossRef
3.
Puymirat E, Fagon JY, Aegerter P et al (2017) Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997–2012. Eur J Heart Failure 19(2):192–200CrossRef
4.
Shaefi S, O’Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, Mahmood E, Talmor D, Shahul S (2015) Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc 4(1):e001462PubMedPubMedCentralCrossRef
5.
Rodriguez M, Sabharwal B, Wei X, Krittanawong C, Verheyen E, Herzog E. The effect of cancer on outcomes on acute heart failure exacerbations: a 5-year nationwide analysis. 2018;71(11 Supplement):A693
6.
Iliescu CA, Grines CL, Herrmann J et al (2016) SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 87(5):E202–E223PubMedCrossRef
7.
Park JY, Al-Hijji M, El Sabbagh A et al (2016) Acute coronary syndrome in active hematological malignancies: a cohort study of 5,300 patients. JACC 67(13 Supplement):585CrossRef
8.
Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70(8):926–938PubMedPubMedCentralCrossRef
9.
Lim SH, Wilson SM, Hunter A, Hill J, Beale P (2013) Takotsubo cardiomyopathy and 5-fluorouracil: getting to the heart of the matter. Case Rep Oncol Med 2013:206765PubMedPubMedCentral
10.
Rohrmann S, Witassek F, Erne P, Rickli H, Radovanovic D (2018) Treatment of patients with myocardial infarction depends on history of cancer. Eur Heart J Acute Cardiovasc Care 7(7):639–645PubMedCrossRef
11.
Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, Cannegieter SC, Jukema JW, Umans VAWM, Schalij MJ, van Boven AJ (2013) Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 112(12):1867–1872PubMedCrossRef
12.
Sulpher J, Dattilo F, Dent S, Turek M, Reaume MN, Johnson C. Acute cardiogenic shock induced by infusional 5-fluorouracil. Case Rep Oncol Med 2014;2014:819396CrossRef
13.
Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–2801PubMedCrossRef
14.
Manual of cardio-oncology. Cardiovascular care in the cancer patient. 2017 ed: Springer International Publishing Switzerland 2017; 2017
15.
Ozaki T, Chiba S, Annen K, Kawamukai Y, Kohno N, Horimoto M (2010) Acute coronary syndrome due to coronary artery compression by a metastatic cardiac tumor. J Cardiol Cases 1(1):e52–ee5PubMedCrossRef
16.
Nogales-Romo MT, Tirado G, Freitas-Ferraz A, Martínez-Losas P, Rodrigo JL, Alswies A, Saiz-Pardo M, Ruiz-Mateos B, Viana-Tejedor A, Fernández-Ortiz A, Macaya C, Núñez-Gil IJ (2016) Coronary embolism of left atrial myxoma coexisting with severe aortic stenosis and atherosclerotic coronary disease. Int J Cardiol 203:315–316PubMedCrossRef
17.
Noguchi M, Yamada Y, Sakakura K, Katayama T, Momomura S, Ako J (2016) Coronary thrombus aspiration revealed tumorous embolism of myxofibrosarcoma from the left atrium. Cardiovasc Interv Ther 31(1):75–78PubMedCrossRef
18.
Antonopoulos AS, Chrysohoou C, Lymperiadis D, Brili S, Tousoulis D (2016) Peripheral and coronary artery embolisms due to left ventricle fibroelastoma. Hell J Cardiol 57(5):368–370CrossRef
19.
20.
Farmakis D, Mantzourani M, Filippatos G (2018) Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail 20(5):907–909PubMedCrossRef
21.
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 131(22):1981–1988PubMedCrossRef
22.
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y.-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39(22):2032–2046PubMedPubMedCentralCrossRef
23.
Giza DE, Lopez-Mattei J, Vejpongsa P et al (2017) Stress-induced cardiomyopathy in cancer patients. Am J Cardiol 120(12):2284–2288PubMedCrossRef
24.
Munoz E, Iliescu G, Vejpongsa P, Charitakis K, Karimzad K, Lopez-Mattei J, Yusuf SW, Marmagkiolis K, Iliescu C (2016) Takotsubo stress cardiomyopathy: “good news” in cancer patients? J Am Coll Cardiol 68(10):1143–1144PubMedCrossRef
25.
Fernandez SF BM, Canty JM Jr. Takotsubo cardiomyopathy following initial chemotherapy presenting with syncope and cardiogenic shock – a case report and literature review. J Clin Exp Cardiol 2:124 2011
26.
Burgdorf C, Kurowski V, Bonnemeier H, Schunkert H, Radke PW (2008) Long-term prognosis of the transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): focus on malignancies. Eur J Heart Fail 10(10):1015–1019PubMedCrossRef
27.
Madias JE (2016) What is/are the trigger(s) of takotsubo syndrome in cancer patients receiving chemotherapy? Int J Cardiol 222:253PubMedCrossRef
28.
Franco TH, Khan A, Joshi V, Thomas B (2008) Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 4(6):1367–1370PubMedPubMedCentralCrossRef
29.
Santos JRU, Brofferio A, Viana B, Pacak K (2018) Catecholamine-induced cardiomyopathy in pheochromocytoma: how to manage a rare complication in a rare disease? Horm Metab Res
30.
31.
Assefa D, Welsch J, Laubner K, Burgdorf C, Kotzerke M (2015) Cardiogenic shock due to atypical Tako-Tsubo cardiomyopathy in a young woman with pheochromocytoma. Deutsche medizinische Wochenschrift (1946). 140(6):422–425CrossRef
32.
Chiang YL, Chen PC, Lee CC, Chua SK (2016) Adrenal pheochromocytoma presenting with Takotsubo-pattern cardiomyopathy and acute heart failure: a case report and literature review. Medicine. 95(36):e4846PubMedPubMedCentralCrossRef
33.
Di Palma G, Daniele GP, Antonini-Canterin F, Piazza R, Nicolosi GL (2010) Cardiogenic shock with basal transient left ventricular ballooning (Takotsubo-like cardiomyopathy) as first presentation of pheochromocytoma. J Cardiovasc Med (Hagerstown) 11(7):507–510CrossRef
34.
Law C, Khaliq A, Guglin M (2013) Reversible cardiogenic shock due to catecholamine-induced cardiomyopathy: a variant of takotsubo? Am J Emerg Med 31(11):1621.e1–1621.e3CrossRef
35.
Hekimian G, Kharcha F, Brechot N et al (2016) Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. Ann Intensive Care 6(1):117PubMedPubMedCentralCrossRef
36.
Flam B, Broome M, Frenckner B, Branstrom R, Bell M (2015) Pheochromocytoma-induced inverted takotsubo-like cardiomyopathy leading to cardiogenic shock successfully treated with extracorporeal membrane oxygenation. J Intensive Care Med 30(6):365–372PubMedCrossRef
37.
Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, Tabib A, Maujean G, Descotes J, Timour Q (2006) Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 25(6):305–309PubMedCrossRef
38.
Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10(8):861–864PubMed
39.
Sellier-Leclerc AL, Belli E, Guerin V, Dorfmuller P, Deschenes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28(9):1875–1879PubMedCrossRef
40.
Alonso JJ, Canovas A, Rubio G (2013) Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma. Med Clin 141(10):459–460CrossRef
41.
Asnani A (2018) Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep 20(6):44PubMedCrossRef
42.
Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Eng J Med 375(18):1749–1755CrossRef
43.
Sauer R, Kiewe P, Desole M et al (2017) Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with nivolumab. Pathologe 38(6):535–539PubMedCrossRef
44.
Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC (2017) Eosinophilic myocarditis. Am J Med Sci 354(5):486–492PubMedCrossRef
45.
Biedka M, Ziolkowska E, Windorbska W (2012) Acute pulmonary embolus in the course of cancer. Contemp Oncol 16(5):388–393
46.
Silva P, Rosales M, Milheiro MJ, Santos LL (2015) Pulmonary embolism in ambulatory oncologic patients. Acta Med Port 28(4):463–468PubMedCrossRef
47.
Bach AG, Neumann J, Taute BM, Surov A (2016) Frequency, cause, and awareness of pulmonary embolism in oncologic patients. Dtsch Med Wochenschr 141(10):713–717PubMedCrossRef
48.
Jones DH, Schlatter MG, Cornelius AS, Neirotti RA (2000) A massive pulmonary tumor embolism after surgical manipulation and biopsy of a pelvic mass. Anesth Analg 90(2):322–323PubMed
49.
Choi EJ, Jin GY (2017) Pulmonary embolism after percutaneous cryoablation for lung cancer: a case report. J Vasc Interv Radiol 28(9):1285–1287PubMedCrossRef
50.
Lin HF, Liao KF, Chang CM, Lin CL, Lai SW, Hsu CY (2018) Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: a case-control study. Medicine. 97(51):e12842PubMedPubMedCentralCrossRef
51.
Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A (2011) Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 16(4):432–444PubMedPubMedCentralCrossRef
52.
Bois MC, Eckhardt MD, Cracolici VM et al (2018) Neoplastic embolization to systemic and pulmonary arteries. J Vasc Surg 68(1):204–212 e7PubMedCrossRef
53.
von Herbay A, Illes A, Waldherr R, Otto HF (1990) Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 66(3):587–592CrossRef
54.
Han S, Kreit J (2013) 1242: Cardiogenic shock from pulmonary tumor thrombotic microangiopathy. 41(12):A319
55.
Ohguchi H, Imaeda K, Hotta A, Kakoi S, Yasuda S, Shimizu Y, Hayakawa A, Mishina H, Hasegawa C, Ito S, Ogawa K, Yagi T, Koyama H, Tanaka T, Kato H, Takahashi S, Joh T (2018) An autopsy case of pulmonary tumor thrombotic microangiopathy due to rapidly progressing colon cancer in a patient with type 2 diabetes. Intern Med 57(17):2533–2539PubMedPubMedCentralCrossRef
56.
Vincent F, Lamblin N, Classe M, Schurtz G, Rauch A, Fertin M, de Groote P (2017) Subacute right heart failure revealing three simultaneous causes of post-embolic pulmonary hypertension in metastatic dissemination of breast cancer. ESC Heart Fail 4(1):75–77PubMedCrossRef
57.
58.
Okubo Y, Wakayama M, Kitahara K, Nemoto T, Yokose T, Abe F, Hiruta N, Sasai D, Shinozaki M, Nakayama H, Ishiwatari T, Shibuya K (2011) Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: morphometric and immunohistochemical analysis of six autopsy cases. Diagn Pathol 6:27PubMedPubMedCentralCrossRef
59.
Tsujimoto N, Miyoshi A, Mimura M, Naka T, Yamasaki M, Yokoi T (2018) Case report: pulmonary tumor thrombotic microangiopathy in a cervical cancer patient. Gynecol Obstet Investig 83(1):99–104CrossRef
60.
Purga SL, Narula N, Horn EM, Karas MG (2015) Pulmonary tumour thrombotic microangiopathy as a cause of new-onset pulmonary hypertension in a patient with metastatic low-grade serous ovarian cancer. BMJ Case Rep 2015
61.
Takayama T, Okura Y, Okada Y, Honma K, Nashimoto A, Sato N, Yokoyama A, Minamino T (2015) Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis: a single-center study of 113 consecutive cancer patients. Int J Clin Oncol 20(5):872–877PubMedCrossRef
62.
Khan UA, Shanholtz CB, McCurdy MT (2017) Oncologic mechanical emergencies. Hematol Oncol Clin North Am 31(6):927–940PubMedCrossRef
63.
Abdelnaby M, Almaghraby A, Saleh Y, Abayazeed R (2018) Pericardial sarcoma. BMJ Case Rep 2018
64.
Chen YY, Huang WC, Huang MH, Lu TM, Hsu CP (2018) The intra-pericardial paraganglioma presenting as ascites and hemopericardium with impending tamponade. Int Heart J 59(3):664–667PubMedCrossRef
65.
Nagarsheth NP, Harrison M, Kalir T, Rahaman J (2006) Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. Int J Gynecol Cancer 16(3):1458–1461PubMedCrossRef
66.
Oka Y, Okada K, Miyake Y, et al. [Three cases of gastric cancer with rare presentation of oncologic emergency]. Gan to kagaku ryoho Cancer & chemotherapy 2016;43(12):2398–2400
67.
Chen X, Miao Q, Yu Y et al Blunt trauma-induced pericardial tamponade after video-assisted thoracoscopic surgery. Ann Thorac Surg
68.
Chung MW, Ha SY, Choi JH, Park HJ, Myung DS, Cho SB, Lee WS, Kim JW, Oh HH, Joo YE (2018) Cardiac tamponade after radiofrequency ablation for hepatocellular carcinoma: case report and literature review. Medicine. 97(49):e13532PubMedPubMedCentralCrossRef
69.
Gonzalo Baron Esquivias RA (2015) Cardiac management of oncology patients. Springer
70.
Sundaram VR, Abbas T (2018) Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: case report. Medicine. 97(44):e12751PubMedPubMedCentralCrossRef
71.
72.
Asai M, Kato Y, Kawai S, et al. Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report2019
73.
Zhao Y, Liu S (2017) Acute cardiac herniation after left Intrapericardial pneumonectomy. J Cardiothorac Vasc Anesth 31(1):270–273PubMedCrossRef
74.
Alimi F, Marzouk M, Mgarrech I, Chemchik H, Limayem F (2016) Cardiac herniation after left intrapericardial pneumonectomy. Asian Cardiovasc Thorac Ann 24(6):590–592PubMedCrossRef
75.
Zandberg FT, Verbeke SJ, Snijder RJ, Dalinghaus WH, Roeffel SM, Van Swieten HA (2004) Sudden cardiac herniation 6 months after right pneumonectomy. Ann Thorac Surg 78(3):1095–1097PubMedCrossRef
76.
Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5(1):91PubMedPubMedCentralCrossRef
77.
Keenan NG, Nicholson AG, Oldershaw PJ (2008) Fatal acute pulmonary hypertension caused by pulmonary tumour thrombotic microangiopathy. Int J Cardiol 124(1):e11–e13PubMedCrossRef
78.
Miyazaki S, Ikeda T, Ito G, Inoue M, Nara K, Nishinaga Y, Hasegawa Y (2017) Pulmonary tumor thrombotic microangiopathy successfully treated with corticosteroids: a case report. J Med Case Rep 11(1):356PubMedPubMedCentralCrossRef
79.
Ogawa A, Yamadori I, Matsubara O, Matsubara H (2013) Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med 52(17):1927–1930PubMedCrossRef
80.
Higo K, Kubota K, Takeda A, Higashi M, Ohishi M (2014) Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med 53(22):2595–2599PubMedCrossRef
81.
82.
83.
Farmakis D, Keramida K, Filippatos G (2018) How to build a cardio-oncology service? Eur J Heart Fail 20(12):1732–1734PubMedCrossRef
Metadata
Title
Cardiogenic shock in cancer
Authors
Kalliopi Keramida
John T. Parissis
Ovidiu Chioncel
Dimitrios Farmakis
Publication date
01-11-2019
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 6/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-019-09819-9

Other articles of this Issue 6/2019

Heart Failure Reviews 6/2019 Go to the issue

ReviewPaper

Research progress on the pathogenesis of CTEPH

ReviewPaper

Immune cell diversity contributes to the pathogenesis of myocarditis

ReviewPaper

Advances in targeted therapy for chronic thromboembolic pulmonary hypertension

ReviewPaper

Takotsubo syndrome: an overview of pathophysiology, diagnosis and treatment with emphasis on cancer patients

ReviewPaper

Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study

ReviewPaper

Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits